Insulet (NASDAQ:PODD) Stock Price Crosses Below Fifty Day Moving Average on Analyst Downgrade

Insulet logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insulet shares fell below their 50-day moving average, trading as low as $139.37 and last quoted at $139.98. Stifel Nicolaus downgraded the stock from Buy to Hold and cut its price target from $180 to $165.
  • Analyst views remain mixed: 11 rate Insulet Buy, 13 Hold and one Sell. MarketBeat reports a consensus Hold rating and an average price target of $185.04.
  • Insulet beat quarterly expectations, posting EPS of $1.99 versus a $1.59 consensus estimate and revenue of $842 million, up 19.2% year over year.
  • MarketBeat previews top five stocks to own in December.

Insulet Corporation (NASDAQ:PODD - Get Free Report) shares crossed below its 50-day moving average during trading on Wednesday after Stifel Nicolaus downgraded the stock from a buy rating to a hold rating. The stock has a 50-day moving average of $142.20 and traded as low as $139.37. Stifel Nicolaus now has a $165.00 price target on the stock, down from their previous price target of $180.00. Insulet shares last traded at $139.98, with a volume of 2,087,669 shares changing hands.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity Group lowered their target price on shares of Insulet from $249.00 to $179.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Jefferies Financial Group reissued a "buy" rating and issued a $200.00 price target on shares of Insulet in a research report on Wednesday, November 4th. Citigroup boosted their price objective on Insulet from $150.00 to $170.00 and gave the stock a "neutral" rating in a report on Thursday, November 5th. BTIG Research lowered shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. Finally, Benchmark cut their price objective on Insulet from $250.00 to $185.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Insulet currently has a consensus rating of "Hold" and a consensus target price of $185.04.

Check Out Our Latest Stock Analysis on PODD

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Insulet in the second quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership lifted its position in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after buying an additional 1,011,369 shares during the period. Soleus Capital Management L.P. lifted its position in Insulet by 64.6% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,726,500 shares of the medical instruments supplier's stock valued at $225,256,000 after acquiring an additional 677,500 shares during the period. Man Group plc bought a new stake in shares of Insulet in the 2nd quarter worth approximately $78,746,000. Finally, Bank of America Corp DE bought a new stake in Insulet in the second quarter worth $64,921,000.

Insulet Trading Down 3.7%

The company has a market cap of $9.71 billion, a P/E ratio of 22.80, a PEG ratio of 1.11 and a beta of 1.06. The stock's 50 day moving average is $142.20 and its 200-day moving average is $171.85. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. The business had revenue of $842.00 million during the quarter, compared to analysts' expectations of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business's revenue for the quarter was up 19.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.24 earnings per share. Research analysts anticipate that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.

Insulet Company Profile

(Get Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insulet Right Now?

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines